5-DAY RUFLOXACIN TREATMENT VERSUS 7-DAY CIPROFLOXACIN TREATMENT IN PATIENTS WITH ACUTE EXACERBATIONS OF CHRONIC-BRONCHITIS - A RANDOMIZED STUDY

被引：6

作者：

CATENA, E

CESANA, M

CARRATU, L

COGO, R

DAMATO, G

GIUNTINI, G

LAURIELLO, G

MIRABELLI, S

RIMOLDI, R

SPADA, E

机构：

[1] MEDIOLANUM FARMACEUT, DEPT MED, I-20143 MILAN, ITALY

[2] UNIV NAPLES, OSPED V MONALDI, DEPT PHTHYSIOL & RESP DIS, NAPLES, ITALY

[3] ORNAGO HOSP, MILAN, ITALY

[4] CARDARELLI HOSP, NAPLES, ITALY

[5] UNIV PISA, PISA, ITALY

[6] G DA PROCIDA HOSP, SALERNO, ITALY

[7] COSTARAINERA HOSP, IMPERIA, ITALY

[8] DI CIRCOLO HOSP, VARESE, ITALY

[9] CONSELICE HOSP, RAVENNA, ITALY

来源：

CLINICAL DRUG INVESTIGATION | 1995年 / 9卷 / 06期

关键词：

D O I：

10.2165/00044011-199509060-00004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In a randomised, multicentre study, 179 hospitalised adults with bacterial exacerbations of chronic bronchitis were given either rufloxacin 200mg once daily (loading dose of 400mg on day 1) [n = 90] or ciprofloxacin 500mg twice daily (n = 89), The duration of treatment was 5 days with rufloxacin and 7 days with ciprofloxacin. In pretreatment sputum samples a pathogen was isolated in 115 patients (64%), the most common isolates being Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. On day 8, clinical cure or improvement was achieved in 89% of the patients in the rufloxacin group and in 91% of the ciprofloxacin group; bacteriological cure was obtained in 79 and 82% of the 2 groups, respectively. At 2-week follow-up, the clinical success rate was 92% with rufloxacin and 99% with ciprofloxacin: the bacteriological success rate was 86 and 85%, respectively. Most of the failures observed with both quinolones were caused by Pseudomonas aeruginosa. Adverse events, mostly gastrointestinal-related, occurred in 9% of the patients in both treatment groups. This study shows that 5-day treatment with rufloxacin once daily is comparable with a conventional 7-day treatment with ciprofloxacin twice daily in patients with bacterial exacerbations of chronic bronchitis caused by susceptible bacteria.

引用

页码：334 / 343

页数：10

共 28 条

[1]

Mattina R., Cocuzza C.E., Cesana M., Et al., In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates, Chemotherapy, 37, (1991)

[2]

Wise R., Andrews J.M., Matthews R., Et al., The in-vitro activity of two new quinolones: rufloxacin and MF 961, J Antimicrob Chemother, 29, (1992)

[3]

Chodosh S., Quinolones in acute exacerbations of chronic bronchitis, The new generation of quinolones, (1990)

[4]

Kisicki J.C., Griess R.S., Ott C.L., Et al., Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers, Antimicrob Agents Chemother, 36, (1992)

[5]

Wise R., Johnson J., O'Sullivan N., Et al., Pharmacokinetics and tissues penetration of rufloxacin, a long acting quinolone antimicrobial agent, J Antimicrob Chemother, 28, (1991)

[6]

Wise R., Andrews J., Imbimbo B.P., Et al., The penetration of rufloxacin into sites of potential infection in the respiratory tract, J Antimicrob Chemother, 32, (1993)

[7]

Mattina R., Bonfiglio G., Cocuzza C.E., Et al., Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses, Chemotherapy, 37, (1991)

[8]

Cogo R., Rimoldi R., Mattina R., Et al., Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections, Ther Drug Monit, 14, pp. 36-41, (1992)

[9]

Cesana M., Broccali G., Imbimbo B.P., Et al., Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration, Int J Clin Pharmacol Ther Toxicol, 29, 4, (1991)

[10]

Dirksen M., Focht J., Boerema J., Rufloxacin once daily in acute exacerbations of chronic bronchitis, Infection, 19, pp. 297-300, (1991)

← 1 2 3 →